All Whitepapers

For pharma companies engaged in digital transformation, LabVantage Pharma is a purpose-built, pre-validated LIMS to bring your labs along the transformation journey.

This whitepaper looks at the requirements for High Throughput Screening, High Content Screening and Surface Plasmon Resonance and makes suggestions for how to make these processes more flexible and repeatable.

This white paper describes how digitizing medicines can drive patient engagement, reduce non-adherence, and enhance supply chain visibility.

This white paper investigates best practices and tangible benefits associated with a risk-based quality management (RBQM) approach to clinical trial management.

Life sciences transformations rarely fail because of what was in the plan. They fail because of what was not. Explore five trends that will determine their success in coming years.

Gain actionable insights from Lash Group experts, leveraging 30+ years of experience launching new programs to help you ensure patient support success.

This white paper investigates best practices and tangible benefits associated with a risk-based quality management (RBQM) approach to clinical trial management.

Industry experts cover how to develop digital patient solutions that address real unmet needs and secure adoption.

In this case study, learn how to increase payer engagement, drive awareness, monitor competition, and leverage insights to enhance strategic plans and launch success.

With bigger patient access and affordability barriers given the new normal of COVID-19, see why field services are more important than ever. Read now.

This whitepaper discusses the importance of patient support programs and why a robust risk mitigation plan is critical to ensure that patients receive their therapy during crises.

In today’s fast-paced marketplace and complicated regulatory environment, operating in the life sciences industry can bring a variety of challenges. From raising capital or addressing pricing pressures to prioritizing development efforts or managing third-party risks, the landscape of Biopharma Finance is changing.

With the future of face-to-face field sales uncertain, how can pharma ensure product messaging reaches the right healthcare audiences and, ultimately, patients?

Compliance officers from the life sciences industry joined together recently to discuss how the COVID-19 pandemic has changed the ways we live and work, and how those changes have impacted the life sciences industry as a whole and will continue to do so in the future.